Silexion Therapeutics (SLXN) Stock Price, News & Analysis

Company Overview

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Key Stats

• Today's Range: $0.93 to $0.97
• 50-Day Range: $0.70 to $1.38
• 52-Week Range: $0.58 to $41.85
• Volume: 188,440 shs
• Average Volume: 5.37 million shs
• Market Capitalization: $8.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

SLXN Stock Analysis - Frequently Asked Questions

How have SLXN shares performed this year?

Silexion Therapeutics' stock was trading at $2.01 at the start of the year. Since then, SLXN stock has decreased by 52.2% and is now trading at $0.9605.
View the best growth stocks for 2025 here.

How were Silexion Therapeutics' earnings last quarter?

Silexion Therapeutics Corp (NASDAQ:SLXN) released its earnings results on Tuesday, May, 13th. The company reported ($0.26) EPS for the quarter.

When did Silexion Therapeutics' stock split?

Shares of Silexion Therapeutics reverse split on the morning of Friday, November 29th 2024. A 1-9 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split.

Who are Silexion Therapeutics' major shareholders?

Top institutional investors of Silexion Therapeutics include Meyer Handelman Co. (0.39%).

How do I buy shares of Silexion Therapeutics?

Shares of SLXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Silexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Silexion Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/14/2025
• Next Earnings (Estimated): 6/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLXN
• Previous Symbol: NASDAQ:SLXN
• CIK: 2022416
• Web: silexion.com
• Phone: 972-2-674-3430
• Fax: 212-572-6395
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +419.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $260,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -249.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.85
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.66 per share
• Price / Cash Flow: 1.46
• Book Value: ($6.63) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 8,692,000
• Free Float: 1,074,000
• Market Cap: $8.37 million
• Optionable: N/A
• Beta: 0.06